Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison K Conlin

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Anticancer Research|July 11, 2006
Dermatological toxicity of ixabepiloneAlison K Conlin, Linda Vahdat
Molecular Diagnosis & Therapy|December 15, 2007
Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancerAlison K Conlin, Andrew D Seidman
Journal of the National Comprehensive Cancer Network : JNCCN|October 12, 2007
Point: combination versus single-agent chemotherapy: the argument for sequential single agentsAlison K Conlin, Andrew D Seidman
Clinical Breast Cancer|July 25, 2008
Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunitiesAlison K Conlin, Andrew D Seidman
Current Oncology Reports|December 14, 2006
Taxanes in breast cancer: an updateAlison K Conlin, Andrew D Seidman
Cancer|December 10, 2015
What does Medicaid expansion mean for cancer screening and prevention? Results from a randomized trial on the impacts of acquiring Medicaid coverageBill J Wright, Alison K Conlin, Heidi L Allen, et al.
Clinical Breast Cancer|August 14, 2010
Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancerAlison K Conlin, Andrew D Seidman, Ariadne Bach, et al.
Clinical Breast Cancer|July 9, 2013
Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancerAndrew D Seidman, Alison K Conlin, Ariadne Bach, et al.
Breast Cancer Research : BCR|July 2, 2025
Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study resultsErika P Hamilton, Manish R Patel, Virginia F Borges, et al.
Journal for Immunotherapy of Cancer|January 28, 2022
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancerBrie Chun, Joanna Pucilowska, ShuChing Chang, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Anticancer Research|July 11, 2006
Dermatological toxicity of ixabepiloneAlison K Conlin, Linda Vahdat
Molecular Diagnosis & Therapy|December 15, 2007
Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancerAlison K Conlin, Andrew D Seidman
Journal of the National Comprehensive Cancer Network : JNCCN|October 12, 2007
Point: combination versus single-agent chemotherapy: the argument for sequential single agentsAlison K Conlin, Andrew D Seidman
Clinical Breast Cancer|July 25, 2008
Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunitiesAlison K Conlin, Andrew D Seidman
Current Oncology Reports|December 14, 2006
Taxanes in breast cancer: an updateAlison K Conlin, Andrew D Seidman
Cancer|December 10, 2015
What does Medicaid expansion mean for cancer screening and prevention? Results from a randomized trial on the impacts of acquiring Medicaid coverageBill J Wright, Alison K Conlin, Heidi L Allen, et al.
Clinical Breast Cancer|August 14, 2010
Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancerAlison K Conlin, Andrew D Seidman, Ariadne Bach, et al.
Clinical Breast Cancer|July 9, 2013
Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancerAndrew D Seidman, Alison K Conlin, Ariadne Bach, et al.
Breast Cancer Research : BCR|July 2, 2025
Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study resultsErika P Hamilton, Manish R Patel, Virginia F Borges, et al.
Journal for Immunotherapy of Cancer|January 28, 2022
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancerBrie Chun, Joanna Pucilowska, ShuChing Chang, et al.
Pageof 3